Previous 10 | Next 10 |
RAMSEY, N.J. and BOCA RATON, Fla., May 21, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops spe...
ADMA Biologics (NASDAQ: ADMA ) has priced its public offering of 11.25M common shares at $4.00 per share, for gross proceeds of ~$45M. More news on: ADMA Biologics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Virtusa (NASDAQ: VRTU ) -24% on Q4 earnings . More news on: Virtusa Corporation, Cellectar Biosciences, Inc., EDAP TMS S.A., Stocks on the move, Read more ...
PITTSBURGH, May 16, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology in...
RAMSEY, N.J. and BOCA RATON, Fla., May 15, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops spe...
Buckeye Partners, L.P. (NYSE: BPL ) +27% on Q1 earnings . More news on: Buckeye Partners, L.P., Cool Holdings, Inc., Westport Fuel Systems Inc., Stocks on the move, Read more ...
The FDA has approved ADMA Biologics' (NASDAQ: ADMA ) Prior Approval Supplement for BIVIGAM (immune globulin intravenous (human), 10% liquid) for its optimized intravenous immune globulin manufacturing process. More news on: ADMA Biologics, Inc., Healthcare stocks news, Stocks on the move...
RAMSEY, N.J. and BOCA RATON, Fla., May 10, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops sp...
ADMA Biologics (NASDAQ: ADMA ): Q1 GAAP EPS of -$0.28 beats by $0.04 . More news on: ADMA Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
RAMSEY, N.J. and BOCA RATON, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops sp...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...